Literature DB >> 7908608

Determination of the allelic frequencies of an L-myc and a p53 polymorphism in human lung cancer.

A Weston1, H M Ling-Cawley, N E Caporaso, E D Bowman, R N Hoover, B F Trump, C C Harris.   

Abstract

The L-myc and p53 genes have been implicated in lung cancer. Both of these genes have restriction fragment length polymorphisms (RFLPs) that could account for differential expression or activity of variant forms. An EcoRI restriction site in the L-myc gene was previously reported to be a predictor of poor prognosis in Japanese lung cancer patients. There are several RFLPs in the p53 gene. In exon 4 there is a polymorphism that codes for either an arginine or proline residue at codon 72. We previously reported the frequency of DNA-RFLPs at these gene loci revealed by EcoRI and AccII respectively. Here we report results from a study comparing lung cancer cases (n = 31) with chronic obstructive pulmonary disease controls (n = 49). No association was found between these RFLPs and disease status. Previous observations that the frequencies of these RFLPs varied by race were confirmed. The p53 arginine allele was found to be more common in Caucasians (0.71) than African-Americans (0.50). The EcoRI restriction site present allele in L-myc was more frequent in African-Americans (0.71) than Caucasians (0.49). Thus, the allelic frequency for L-myc was similar in African-Americans to that reported for Japanese, and the allelic frequency for p53 was similar in Caucasians to that reported for Japanese.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7908608     DOI: 10.1093/carcin/15.4.583

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  16 in total

1.  DNA sequence variants of p53: cancer and aging.

Authors:  Y Sun; C Keshava; D S Sharp; A Weston; E C McCanlies
Journal:  Am J Hum Genet       Date:  1999-12       Impact factor: 11.025

2.  Association between the TP53 polymorphisms and lung cancer risk: a meta-analysis.

Authors:  Xiang-Hua Ye; Zhi-Bin Bu; Jie Feng; Ling Peng; Xin-Biao Liao; Xin-Li Zhu; Xiao-Li Sun; Hao-Gang Yu; Dan-Fang Yan; Sen-Xiang Yan
Journal:  Mol Biol Rep       Date:  2013-11-23       Impact factor: 2.316

Review 3.  The association between TP53 Arg72Pro polymorphism and lung cancer susceptibility: evidence from 30,038 subjects.

Authors:  Qian Qiao; Weiguo Hu
Journal:  Lung       Date:  2013-04-18       Impact factor: 2.584

Review 4.  Breast cancer in African American women: epidemiology and tumor biology.

Authors:  B J Trock
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

5.  Role of glutathione-S-transferase and codon 72 of P53 genotypes in epithelial ovarian cancer patients.

Authors:  Elaine Cristina Morari; Andre Bacellar Costa Lima; Natassia Elena Bufalo; Janaina Luisa Leite; Fabiana Granja; Laura Sterian Ward
Journal:  J Cancer Res Clin Oncol       Date:  2006-05-19       Impact factor: 4.553

6.  p53 codon 72 polymorphism is associated with susceptibility to hepatocellular carcinoma in the Turkish population: a case-control study.

Authors:  Ahmet Taner Sümbül; Hikmet Akkız; Süleyman Bayram; Aynur Bekar; Ersin Akgöllü; Macit Sandıkçı
Journal:  Mol Biol Rep       Date:  2011-05-24       Impact factor: 2.316

7.  P53 polymorphism and lung cancer susceptibility: a pooled analysis of 32 case-control studies.

Authors:  Shengming Dai; Chen Mao; Lijun Jiang; Guisheng Wang; Hongge Cheng
Journal:  Hum Genet       Date:  2009-04-09       Impact factor: 4.132

8.  MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility.

Authors:  Nathan A Ellis; Dezheng Huo; Ozlem Yildiz; Lisa J Worrillow; Mekhala Banerjee; Michelle M Le Beau; Richard A Larson; James M Allan; Kenan Onel
Journal:  Blood       Date:  2008-04-21       Impact factor: 22.113

9.  Association between p53 codon 72 genetic polymorphism and tobacco use and lung cancer risk.

Authors:  Dante D Cáceres; Luis A Quiñones; Jane C Schroeder; Leonel D Gil; Carlos E Irarrázabal
Journal:  Lung       Date:  2009-01-07       Impact factor: 2.584

10.  p53 codon 72 polymorphism and breast cancer risk: A meta-analysis.

Authors:  Jing Hou; Yuan Jiang; Wenru Tang; Shuting Jia
Journal:  Exp Ther Med       Date:  2013-03-20       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.